LAM-002A

Status
Phase 2
Condition
COVID-19
Intervention Type
Oral Drug
Funder Type
Industry

Drug Details

LAM-002A is an oral selective kinase inhibitor.

Study Purpose

This is a clinical trial to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standards supportive care in an outpatient setting.

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >